BioCryst Pharmaceuticals
56
2
3
38
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
23.2%
13 terminated/withdrawn out of 56 trials
74.5%
-12.0% vs industry average
21%
12 trials in Phase 3/4
55%
21 of 38 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (56)
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Role: lead
Berotralstat Treatment in Children With Hereditary Angioedema
Role: lead
A Study of Avoralstat In Participants With Diabetic Macular Edema
Role: lead
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Role: lead
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Role: lead
Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
Role: lead
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Role: lead
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy
Role: lead
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Role: lead
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy
Role: lead
Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan
Role: lead
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Role: lead
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Role: lead
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
Role: lead
First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
Role: lead
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
Role: lead
A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
Role: lead
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
Role: lead
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Role: lead
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
Role: lead